Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Mayo Clin Proc. 2021 Nov 9;96(12):3021–3029. doi: 10.1016/j.mayocp.2021.06.025

Table 3.

Serum Glucose and Other Glycemic Indices After One Year of TKI Therapy

Dasatinib Imatinib Difference * P-value
Number 12 26
Serum Glucose (mg/dL) −31.4 ± 34.2 12.3 ± 43.6 −43.7 0.005
Total daily insulin (Units) −23.5 ± 22.2 5.3 ± 19.2 −28.8 0.08
Other antihyperglycemic medications 0.0 ± 0.0 0.04 ± 0.45 −0.04 0.66
Weight (kg) −1.62 ± 4.89 3.18 ± 9.30 4.80 0.045
Body mass (%) −1.7 ± 2.3 3.6 ± 8.9 5.3 0.03
*

P -values obtained using a 2-tailed two-sample t-test assuming unequal variances for continuous variables, or Fisher’s exact test for categorical variables